Gastrointestinal Stromal Tumors (GISTs) Market Outlook

Thelansis’s “Gastrointestinal Stromal Tumors (GISTs) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Gastrointestinal Stromal Tumors treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Gastrointestinal Stromal Tumors (GISTs) Overview

Gastrointestinal Stromal Tumors (GISTs) are the most common mesenchymal neoplasms of the digestive tract, originating from the interstitial cells of Cajal. Approximately 80–85% of sporadic cases harbor mutually exclusive driver mutations in the receptor tyrosine kinases KIT or PDGFRA, which constitutively hyperactivate downstream RAS-MAPK and PI3K-AKT proliferative signaling loops. While GISTs can develop anywhere along the alimentary canal, they are most prevalent in the stomach (60%) and small intestine (30%), causing insidious fatigue, abdominal pain, dysphagia, early satiety, or mechanical obstruction. GISTs lacking these canonical alterations are termed “wild-type” (wt-GIST) and must be molecularly stratified into Succinate Dehydrogenase (SDH)-deficient variants and non-SDH-deficient syndromic lines. Notably, multifocal wild-type GISTs manifest in approximately 7% of patients with Neurofibromatosis Type 1 (NF1), concentrated almost exclusively in the small intestine (90%). These syndromic tumors are driven by somatic mutations or loss-of-heterozygosity of the remaining wild-type NF1 allele, eliminating neurofibromin’s tumor-suppressive capacity and driving massive, unchecked RAS-MAPK pathway activation. Unlike classic sporadic tumors that highly respond to frontline imatinib, NF1-associated GISTs are intrinsically resistant to standard first-line tyrosine kinase inhibitors, requiring early surgical resection with negative margins for localized disease, and investigation into downstream MEK inhibitors or salvage switch-control TKIs within active clinical trials for advanced or progressive disease.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025–2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc..

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets,etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)